- \n
- Q3 2019 Group sales growth of +16.0% as reported and +14.5%1<\/sup>\u00a0at constant exchange rates and consolidation scope, driven by Specialty Care sales growth of 16.5%1<\/sup>, reflecting strong double-digit momentum of Somatuline\u00ae\u00a0(lanreotide) and the continued growth from Cabometyx\u00ae\u00a0(cabozantinib) and Decapeptyl\u00ae\u00a0(triptorelin)<\/li>\n
- YTD Group sales growth of +15.7% as reported and +14.3%1<\/sup>\u00a0at constant exchange rates and consolidation scope fueled by strong Specialty Care sales growth of 16.8%1<\/sup><\/li>\n
- Full Year 2019 guidance confirmed with Group sales growth greater than +14.0% at constant currency and consolidation scope1\u00a0and Core Operating margin at around 30.0% of net sales<\/li>\n<\/ul>\n
Recent pipeline highlights<\/u><\/b><\/p>\n
- \n
- Positive interim Phase 1\/2 clinical data evaluating Onivyde\u00ae\u00a0(liposomal irinotecan) as first-line treatment for metastatic pancreatic cancer presented at ESMO 21st World Congress on Gastrointestinal Cancer<\/li>\n
- Positive interim data from seamless Phase 2\/3 clinical trial evaluating Onivyde as a second-line treatment for small cell lung cancer (SCLC) presented at the IASLC 2019 World Conference on Lung Cancer<\/li>\n
- FDA approval of Dysport\u00ae\u00a0(abobotulinumtoxinA) for the treatment of upper limb spasticity in children two years of age and older, excluding spasticity caused by cerebral palsy (CP)<\/li>\n
- In-licensing of BLU-782 from Blueprint Medicines, a highly selective ALK2 inhibitor in Phase 1 development for the treatment of fibrodysplasia ossificans progressiva (FOP)<\/li>\n
- Palovarotene regulatory submission to the FDA for the episodic treatment of FOP now expected in Q1 2020 as a result of the processing of additional supportive data.<\/li>\n<\/ul>\n
Key figures<\/u><\/b><\/p>\n
Unaudited IFRS consolidated sales<\/em><\/p>\n
\n
\n \u00a0 <\/td>\n Third Quarter<\/strong> <\/td>\n \u00a0 <\/td>\n Nine Months<\/strong> <\/td>\n<\/tr>\n \n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n<\/tr>\n \n (in million euros) <\/td>\n 2019<\/strong> <\/td>\n 2018<\/strong> <\/td>\n % Variation <\/td>\n %
Variation
at constant currency and consolidation scope1<\/sup> <\/td>\n\u00a0 <\/td>\n 2019<\/strong> <\/td>\n 2018<\/strong> <\/td>\n % Variation <\/td>\n %
Variation at constant currency and consolidation scope 1<\/sup> <\/td>\n<\/tr>\n\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n<\/tr>\n \n Specialty Care<\/strong> <\/td>\n 574.2<\/strong> <\/td>\n 484.1<\/strong> <\/td>\n 18.6%<\/em><\/strong> <\/td>\n 16.5%<\/em><\/strong> <\/td>\n \u00a0 <\/td>\n 1,674.1<\/strong> <\/td>\n 1,404.2<\/strong> <\/td>\n 19.2%<\/em><\/strong> <\/td>\n 16.8%<\/em><\/strong> <\/td>\n<\/tr>\n \n Consumer Healthcare<\/strong>2<\/sup><\/strong> <\/td>\n 70.6<\/strong> <\/td>\n 71.9<\/strong> <\/td>\n -1.8%<\/em><\/strong> <\/td>\n 0.1%<\/em><\/strong> <\/td>\n \u00a0 <\/td>\n 200.2<\/strong> <\/td>\n 216.2<\/strong> <\/td>\n -7.4%<\/em><\/strong> <\/td>\n -2.4%<\/em><\/strong> <\/td>\n<\/tr>\n \n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n \u00a0 <\/td>\n<\/tr>\n \n Group sales<\/strong> <\/td>\n 644.7<\/strong> <\/td>\n 555.9<\/strong> <\/td>\n 16.0%<\/em><\/strong> <\/td>\n 14.5%<\/em><\/strong> <\/td>\n \u00a0 <\/td>\n 1,874.3<\/strong> <\/td>\n 1,620.4<\/strong> <\/td>\n 15.7%<\/em><\/strong> <\/td>\n 14.3%<\/em><\/strong> <\/td>\n<\/tr>\n<\/table>\n David Meek, Chief Executive Officer of Ipsen<\/b>\u00a0stated:\u00a0\u201cIn the third quarter, we continued to execute on our objectives with a strong performance of our Specialty Care business, including double-digit growth of Somatuline in both the U.S. and Europe. With our excellent performance year-to-date, we are increasingly confident in our ability to achieve our 2019 financial guidance.<\/em>
We remain focused on the successful execution of the palovarotene program to bring the first therapeutic treatment to FOP patients as expeditiously as possible. We also continue to deliver on our external innovation strategy. The recent in-licensing of BLU-782 reinforces our leadership in FOP with a different and potentially complementary mechanism of action to palovarotene, expands our portfolio approach in this complex ultra-rare bone disorder and leverages our clinical and commercial capabilities. Advancing our pipeline remains a key focus going forward to deliver on our growth strategy and to bring additional value to patients and shareholders.\u201d<\/em><\/p>\nThird quarter 2019 sales highlights<\/u><\/b>
Note: Unless stated otherwise, all variations in sales are stated excluding foreign exchange impacts (currency effects established by recalculating net sales for the relevant period at the exchange rates from the previous period)<\/em><\/p>\n\n
\n (in million euros) <\/td>\n 2019<\/strong> <\/td>\n 2018<\/strong> <\/td>\n % Variation <\/td>\n %
Variation
at constant currency and consolidation scope1<\/sup> <\/td>\n<\/tr>\n\n \u00a0 <\/td>\n \u00a0<\/td>\n \u00a0<\/td>\n \u00a0<\/td>\n \u00a0<\/td>\n<\/tr>\n \n Specialty Care<\/strong> <\/td>\n 574.2<\/strong> <\/td>\n 484.1<\/strong> <\/td>\n 18.6%<\/em><\/strong> <\/td>\n 16.5%<\/em><\/strong> <\/td>\n<\/tr>\n \n Somatuline\u00ae<\/sup> <\/td>\n 264.0 <\/td>\n 217.0 <\/td>\n 21.7%<\/em> <\/td>\n 18.8%<\/em> <\/td>\n<\/tr>\n \n Decapeptyl\u00ae<\/sup> <\/td>\n 98.9 <\/td>\n 89.2 <\/td>\n 10.9%<\/em> <\/td>\n 10.5%<\/em> <\/td>\n<\/tr>\n \n \u00a0Cabometyx\u00ae<\/sup> <\/td>\n 64.5 <\/td>\n 38.8 <\/td>\n 66.5%<\/em> <\/td>\n 66.3%<\/em> <\/td>\n<\/tr>\n \n Onivyde\u00ae<\/sup> <\/td>\n 26.1 <\/td>\n 26.9 <\/td>\n -3.0%<\/em> <\/td>\n \u00a0-7.3%<\/em> <\/td>\n<\/tr>\n \n Dysport\u00ae<\/sup> <\/td>\n 97.4 <\/td>\n 87.7 <\/td>\n 11.0%<\/em> <\/td>\n \u00a08.8%<\/em> <\/td>\n<\/tr>\n \n Consumer Healthcare<\/strong> <\/td>\n 70.6<\/strong> <\/td>\n 71.9<\/strong> <\/td>\n -1.8%<\/em><\/strong> <\/td>\n \u00a00.1%<\/em><\/strong> <\/td>\n<\/tr>\n \n Smecta\u00ae<\/sup> <\/td>\n 34.1 <\/td>\n 32.8 <\/td>\n 4.1%<\/em> <\/td>\n \u00a0 2.5%<\/em> <\/td>\n<\/tr>\n \n Forlax\u00ae<\/sup> <\/td>\n 10.5 <\/td>\n 9.5 <\/td>\n 10.6%<\/em> <\/td>\n \u00a0 9.7%<\/em> <\/td>\n<\/tr>\n \n Tanakan\u00ae<\/sup> <\/td>\n 8.8 <\/td>\n 9.6 <\/td>\n -8.8%<\/em> <\/td>\n -10.0%<\/em> <\/td>\n<\/tr>\n \n Group sales<\/strong> <\/td>\n 644.7<\/strong> <\/td>\n 555.9<\/strong> <\/td>\n 16.0%<\/em><\/strong> <\/td>\n 14.5%<\/em><\/strong> <\/td>\n<\/tr>\n<\/table>\n \u00a0<\/p>\n
Q3 2019 Group sales<\/b>\u00a0grew 14.5%1<\/sup>\u00a0to \u20ac644.7 million.
Sales of\u00a0Specialty Care<\/b>\u00a0products reached \u20ac574.2 million, up 16.5% year-on-year.
Somatuline<\/b>\u00a0sales reached \u20ac264.0 million, up 18.8%, year-on-year, driven by 20.0% growth in North America, double-digit growth in key European countries and good performance in Japan.
Decapeptyl<\/b>\u00a0sales reached \u20ac98.9 million, up 10.5% year-on-year, driven by volume and market share gains in Europe and double-digit growth in China.
Cabometyx\u00a0<\/b>sales reached \u20ac64.5 million, growing 66.3% year-on-year, driven by the good performance in all launched European countries and additional launches in Asia and Oceania.\u00a0<\/b>
Onivyde<\/b>\u00a0sales reached \u20ac26.1 million, down 7.3% year-on-year, impacted by limited shipments to Ipsen\u2019s ex-U.S. partner in the third quarter.
Dysport<\/b>\u00a0sales reached \u20ac97.4 million, up 8.8% year-on-year, driven by the solid performance in the U.S. in the therapeutics and aesthetics markets, as well as growth from Galderma in Europe.
Consumer Healthcare\u00a0<\/b>product sales totaled \u20ac70.6 million, stable at +0.1%1<\/sup>, driven by Smecta growth of 2.5% year-on-year, from the good performance in France and in China despite the new hospital competitive pricing environment, and Forlax growth of 9.7% year-on-year. Tanakan sales reached \u20ac8.8 million, down 10.0% year-on-year, due to competitive pressure in emerging countries and a market slowdown in France.<\/p>\nConfirmation of Full Year 2019 guidance<\/u><\/b><\/p>\n
- YTD Group sales growth of +15.7% as reported and +14.3%1<\/sup>\u00a0at constant exchange rates and consolidation scope fueled by strong Specialty Care sales growth of 16.8%1<\/sup><\/li>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[],"tags":[],"class_list":["post-3684","press_release","type-press_release","status-publish","hentry","entry"],"acf":[],"yoast_head":"\n